Literature DB >> 24452261

Pharmacogenetics at 50: genomic personalization comes of age.

Thomas J Urban1, David B Goldstein.   

Abstract

The study of the genetics of drug responses has a long history but has provided only a few examples of gene variants that are relevant clinically. Here, we discuss the current state of the pharmacogenomics field with emphasis on the potential of data generated through drug development in order to shed new light on genetic variants predictive of therapeutic outcomes-and likewise the potential of pharmacogenomics to improve clinical trial design. We note some examples in which data from clinical trials have already provided clear pharmacogenomic insights and suggest ways in which genomic technology might be used successfully in drug development.

Mesh：

Year:  2014        PMID： 24452261     DOI： 10.1126/scitranslmed.3005237

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  10 in total

1.  Female hormones prevent a catastrophic epilepsy in male mice.

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 2.  Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population.

Authors:  Chao Luo; Junyan Liu; Xu Wang; Xiaoyuan Mao; Honghao Zhou; Zhaoqian Liu
Journal:  Neurosci Bull       Date:  2019-01-03       Impact factor: 5.203

Review 3.  Testing cardiovascular drug safety and efficacy in randomized trials.

Authors:  Garret A FitzGerald
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

Review 4.  The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Authors:  J W Lee; F Aminkeng; A P Bhavsar; K Shaw; B C Carleton; M R Hayden; C J D Ross
Journal:  Clin Genet       Date:  2014-05-09       Impact factor: 4.438

5.  Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.

Authors:  L R Parham; L P Briley; L Li; J Shen; P J Newcombe; K S King; A J Slater; A Dilthey; Z Iqbal; G McVean; C J Cox; M R Nelson; C F Spraggs
Journal:  Pharmacogenomics J       Date:  2015-05-19       Impact factor: 3.550

6.  RNAseq analysis of heart tissue from mice treated with atenolol and isoproterenol reveals a reciprocal transcriptional response.

Authors:  Andrea Prunotto; Brian J Stevenson; Corinne Berthonneche; Fanny Schüpfer; Jacques S Beckmann; Fabienne Maurer; Sven Bergmann
Journal:  BMC Genomics       Date:  2016-09-07       Impact factor: 3.969

7.  The GenomeAsia 100K Project enables genetic discoveries across Asia.

Authors: 
Journal:  Nature       Date:  2019-12-04       Impact factor: 49.962

8.  Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.

Authors:  H W Nam; V M Karpyak; D J Hinton; J R Geske; A M C Ho; M L Prieto; J M Biernacka; M A Frye; R M Weinshilboum; D-S Choi
Journal:  Transl Psychiatry       Date:  2015-08-18       Impact factor: 6.222

Review 9.  From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine.

Authors:  Jeremy R Everett
Journal:  Front Pharmacol       Date:  2016-09-08       Impact factor: 5.810

10.  PharmaKU: A Web-Based Tool Aimed at Improving Outreach and Clinical Utility of Pharmacogenomics.

Authors:  Sumi Elsa John; Arshad Mohamed Channanath; Prashantha Hebbar; Rasheeba Nizam; Thangavel Alphonse Thanaraj; Fahd Al-Mulla
Journal:  J Pers Med       Date:  2021-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.